Hypercoagulability in sickle cell disease

new approaches to an old problem.

Kenneth Ataga, Nigel S. Key

Research output: Contribution to journalReview article

107 Citations (Scopus)

Abstract

Patients with sickle cell disease (SCD) exhibit high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, abnormal activation of the fibrinolytic system, and increased tissue factor expression, even in the non-crisis steady state. In addition, platelets and other cellular elements are chronically activated in the non-crisis state. Despite an abundance of evidence for coagulation and platelet activation, it remains uncertain whether these changes contribute to the pathophysiology of SCD or are, rather, simple epiphenomena. With the occurrence of macrovascular thrombotic complications in SCD, as well as the recognition that soluble CD40 ligand is biologically active in SCD, coagulation and platelet activation may indeed play a role in SCD pathophysiology. Defining a role for hypercoagulability in SCD requires further understanding of its pathogenesis. Furthermore, the conduct of well-controlled clinical trials using anticoagulants and antiplatelet agents and using a variety of clinical endpoints is warranted.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Thrombophilia
Sickle Cell Anemia
Platelet Activation
Anticoagulants
CD40 Ligand
Platelet Aggregation Inhibitors
Controlled Clinical Trials
Thromboplastin
Thrombin
Blood Platelets
Proteins

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{7799b6c890484218b121f05a04f3d2c8,
title = "Hypercoagulability in sickle cell disease: new approaches to an old problem.",
abstract = "Patients with sickle cell disease (SCD) exhibit high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, abnormal activation of the fibrinolytic system, and increased tissue factor expression, even in the non-crisis steady state. In addition, platelets and other cellular elements are chronically activated in the non-crisis state. Despite an abundance of evidence for coagulation and platelet activation, it remains uncertain whether these changes contribute to the pathophysiology of SCD or are, rather, simple epiphenomena. With the occurrence of macrovascular thrombotic complications in SCD, as well as the recognition that soluble CD40 ligand is biologically active in SCD, coagulation and platelet activation may indeed play a role in SCD pathophysiology. Defining a role for hypercoagulability in SCD requires further understanding of its pathogenesis. Furthermore, the conduct of well-controlled clinical trials using anticoagulants and antiplatelet agents and using a variety of clinical endpoints is warranted.",
author = "Kenneth Ataga and Key, {Nigel S.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1182/asheducation-2007.1.91",
language = "English (US)",
pages = "91--96",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Hypercoagulability in sickle cell disease

T2 - new approaches to an old problem.

AU - Ataga, Kenneth

AU - Key, Nigel S.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Patients with sickle cell disease (SCD) exhibit high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, abnormal activation of the fibrinolytic system, and increased tissue factor expression, even in the non-crisis steady state. In addition, platelets and other cellular elements are chronically activated in the non-crisis state. Despite an abundance of evidence for coagulation and platelet activation, it remains uncertain whether these changes contribute to the pathophysiology of SCD or are, rather, simple epiphenomena. With the occurrence of macrovascular thrombotic complications in SCD, as well as the recognition that soluble CD40 ligand is biologically active in SCD, coagulation and platelet activation may indeed play a role in SCD pathophysiology. Defining a role for hypercoagulability in SCD requires further understanding of its pathogenesis. Furthermore, the conduct of well-controlled clinical trials using anticoagulants and antiplatelet agents and using a variety of clinical endpoints is warranted.

AB - Patients with sickle cell disease (SCD) exhibit high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, abnormal activation of the fibrinolytic system, and increased tissue factor expression, even in the non-crisis steady state. In addition, platelets and other cellular elements are chronically activated in the non-crisis state. Despite an abundance of evidence for coagulation and platelet activation, it remains uncertain whether these changes contribute to the pathophysiology of SCD or are, rather, simple epiphenomena. With the occurrence of macrovascular thrombotic complications in SCD, as well as the recognition that soluble CD40 ligand is biologically active in SCD, coagulation and platelet activation may indeed play a role in SCD pathophysiology. Defining a role for hypercoagulability in SCD requires further understanding of its pathogenesis. Furthermore, the conduct of well-controlled clinical trials using anticoagulants and antiplatelet agents and using a variety of clinical endpoints is warranted.

UR - http://www.scopus.com/inward/record.url?scp=57149146076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149146076&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2007.1.91

DO - 10.1182/asheducation-2007.1.91

M3 - Review article

SP - 91

EP - 96

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -